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Acute and chronic exposure to organophosphates (OPs), including 
agricultural pesticides, industrial chemicals, and chemical 
warfare agents, remain a significant worldwide health risk. The 
mechanisms by which OPs alter development and cognition in 
exposed individuals remain poorly understood, in part due to the 
large number of structurally diverse OPs and the wide range of 
affected proteins and signaling pathways. To investigate the 
influence of structure on OP targets in mammalian systems, we 
have developed a series of probes for activity-based protein 
profiling (ABPP) featuring two distinct reactive groups that 
mimic OP chemical reactivity. FOP features a fluorophosphonate 
moiety, and PODA and CODA utilize a dialkynyl phosphate ester; 
both reactive group types target serine hydrolase activity. As 
the oxon represents the highly reactive and toxic functional 
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group of many OPs, the new probes described herein enhance our 
understanding of tissue-specific reactivity of OPs. 
Chemoproteomic analysis of mouse tissues treated with the probes 
revealed divergent protein profiles, demonstrating the influence 
of probe structure on protein targeting. These targets also vary 
in sensitivity towards different OPs. The simultaneous use of 
multiple probes in ABPP experiments may therefore offer more 
comprehensive coverage of OP targets; FOP consistently labeled 
more targets in both brain and liver than PODA or CODA, 
suggesting the dialkyne warhead is more selective for enzymes in 
major signaling pathways than the more reactive 
fluorophosphonate warhead. Additionally, the probes can be used 
to assess reactivation of OP-inhibited enzymes by N-oximes and 
may serve as diagnostic tools for screening of therapeutic 
candidates in a panel of protein targets. These applications 
will help clarify the short- and long-term effects of OP 
toxicity beyond acetylcholinesterase inhibition, investigate 
potential points of convergence for broad spectrum therapeutic 
development, and support future efforts to screen candidate 
molecules for efficacy in various model systems.
TEXT
Introduction
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Organophosphate (OP) pesticides, first developed in the 
1940s, have been used worldwide in household and agricultural 
settings.1, 2 OPs have also long been used as chemical warfare 
agents and remain a threat to first responders and civilians.3 
Currently, dozens of structurally diverse OPs are registered for 
agricultural, industrial, and pharmaceutical applications. While 
many OP pesticides, such as chlorpyrifos and malathion, display 
limited toxicity towards humans, metabolism of the thion species 
by cytochrome p450 oxidation and potentially other oxidative 
processes can generate the oxon, which serves as the active 
pesticide agent.4 Reactivity and metabolism of the oxon can 
proceed through a variety of different processes (Figure 1), 
such as hydrolysis by OP hydrolases (OPHs) and inhibition of 
various enzyme targets.
The acute toxicity of OPs can be attributed to their 
ability to covalently modify a serine residue in the active site 
of AChE (Figure 1). AChE inhibition results in accumulation of 
acetylcholine at neuromuscular junctions, which causes 
overstimulation of the nervous system and can lead to 
respiratory failure, convulsions, or paralysis.5 While the 
primary target of OPs is AChE, these compounds also inhibit 
other proteins in mammalian systems.6, 7 Regulatory and 
authoritative bodies have established public and occupational 
exposure limits based on cholinesterase inhibition, but 
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examination of recent work suggests that non-cholinergic targets 
maybe as sensitive or more sensitive than acetylcholinesterase 
inhibition. Perturbation of these enzyme functions, particularly 
in the brain, is thought to be responsible for the long-term 
detrimental impacts of organophosphates on development and 
cognition,8, 9 which are still poorly understood.4
In order to understand the potential impacts of OP exposure 
beyond cholinergic targets, we sought to develop a series of 
molecular probes that could be used to broadly profile the 
targets of OPs in a variety of tissues using the activity-based 
protein profiling (ABPP) approach.  ABPP employs activity-based 
probes (ABPs) that target enzymes based on their activity toward 
specific substrates.10, 11 ABPP has been used to study protein 
targets of serine hydrolases,12 glutathione S-transferases,13 
cellulases, and other enzymes.14 To date, ABPP of secondary 
targets of OPs and OP-enzyme interactions has primarily focused 
on the use of fluorophosphonate-based probes,15-18 which have been 
widely used to study serine hydrolases.19 Recent efforts by 
Carmany et al. to profile targets of the organophosphate 
chemical weapon, VX agent, utilized an ABP probe featuring a 
thermal rearrangement to generate the active probe.20 Notably, 
OPs span a range of structures in terms of their reactive 
functionalities and leaving groups; these steric and electronic 
differences may affect their ability to bind and inhibit 
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different proteins. A major challenge in OP therapeutic research 
has been addressing the divergent responses of OP-inhibited AChE 
toward chemical reactivating compounds and lack of a broad 
spectrum therapeutics for treatment of OP poisoning.5, 21 Some of 
the resistance to reactivation may arise from varying aging 
rates, depending on the electronics of the phosphate ester and 
the nature of the enzyme active site.22, 23 It is also established 
that OP agents have differing levels of inhibition of the 
primary target, AChE, due to steric and electronic differences 
in both the leaving group and alkoxy substituents.24, 25 AChE 
inhibition may also differ across model organisms due to 
variation in the enzyme active site architecture.26 Collectively, 
these observations underscore the complications associated with 
understanding toxicity for a wide range of OPs, as well as 
inherent differences in enzyme structure across model organisms 
and in different tissue types.
Given the structural diversity of OPs and observed 
differences in the response of OPs to various therapeutics, we 
anticipated that ABPs for OPs may display divergent profiles 
dependent upon structure. This hypothesis is supported by 
previous measurements of OP binding by AChE and studies 
demonstrating that structural changes to ABPs affect their 
ability to inhibit AChE and other targets.27, 28 Thereby, we 
sought to design new OP probes with structural features that 
Page 6 of 43
ACS Paragon Plus Environment






























































would mimic the sterics, electronics, and reactive 
functionalities of representative OP compounds to examine the 
effect of probe structure on identified protein target in 
mammalian tissues (Figure 2A). We developed a new 
fluorophosphonate for OP profiling (FOP) by incorporating a 
benzyl group rather than an aliphatic or PEG linker, which 
provided structural similarity to the aromatic groups of PO and 
CPO. Additionally, we designed and synthesized two probes 
containing a dialkynyl phosphate ester as a new reactive group 
for ABPP of serine hydrolases; covalent modification of the 
enzyme occurs via a mechanism similar to that of phosphate ester 
pesticides, and the phenolic leaving groups are identical.
Following validation that the ABPs inhibit AChE, the probes 
were applied to mouse brain and liver lysate to evaluate the 
impact of ABP structure and reactivity on identified targets, 
including shared and unique targets for each probe and 
susceptibility of targets to competition by OP pesticides 
(Figure 2B). We determined that the probes are excellent 
surrogates for authentic OPs and can be used to profile the 
broad and diverse impact of OPs on mammalian enzymes. Using 
these new probes, our research provides a significantly improved 
understanding of the targets of OPs across tissues. These 
results will help inform future studies exploring the long-term 
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impacts of OPs on development, as well as improve probe design 
for ABPP and usage in model systems.
Experimental Procedures
General materials and methods
Considering previous observations that fluorophosphonate 
probes hydrolyze when stored under neat conditions,29 probes were 
dissolved in anhydrous DMSO shortly after synthesis and 
characterization and divided into aliquots for longer term 
storage, avoiding freeze-thaw cycles.
Organophosphates were purchased from the following 
suppliers and used without further purification: paraoxon (Chem 
Cruz, sc-208151, Lot D2117) and chlorpyrifos oxon (98.8%, Chem 
Service, MET-114590, Lot 525430). Stock solutions of OPs were 
prepared in dry DMSO and stored at -70 °C, avoiding freeze-thaw 
cycles. 2-pralidoxime chloride (2-PAM) was purchased from Sigma-
Aldrich. Stock solutions of 2-PAM were prepared freshly on the 
day of the experiment in MilliQ water and maintained on ice.
Electric eel acetylcholinesterase (Sigma-Aldrich) was 
prepared at 2 mg/mL concentration in 100 mM PBS, pH 7.4, with 1 
mg/mL bovine serum albumin (BSA) and stored at 4 °C for up to 3 
months.
Protein concentrations were determined using a 
bicinchoninic acid (BCA) assay (Thermo Scientific Pierce). 
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Colorimetric assays were performed using a Molecular Devices 
plate reader.
Synthetic procedures are described in the Supporting 
Information.
Probe-mediated fluorescent labeling for SDS-PAGE
Tissue lysate samples (50 µL at 1 mg/mL total protein 
concentration) were treated with 1 µL DMSO vehicle control or 1 
µL 2.5 mM OP stock solution in DMSO (final concentration 50 µM 
OP). Samples were incubated for 30 min at 37 °C with agitation 
and then treated with 1 µL of a 500 µM probe stock (final probe 
concentration 10 µM) for 1 hr at 37 °C with agitation. Samples 
were then subjected to click chemistry for 1 hr at r.t. by 
adding 0.5 µL of 3 mM carboxytetramethylrhodamine (TAMRA) azide, 
1 µL 250 mM sodium ascorbate, 1 µL 100 mM tris(3-
hydroxypropyltriazolylmethyl)amine (THPTA), and 1 µL 200 mM 
CuSO4. Samples were precipitated by adding 100 µL cold MeOH and 
allowing to stand at -70 °C overnight. Precipitated protein was 
pelleted by centrifuging at 14,000 x g for 15 min at 4 °C, air-
dried after removal of supernatant, and reconstituted with 32.5 
µL 1.2% SDS in 1X PBS, 12.5 µL 4X LDS buffer, and 5 µL 10X 
reducing agent. Samples were sonicated briefly and then 
denatured at 85 °C for 10 min. Samples (15 µL per well) were 
loaded onto Invitrogen NuPAGE 4-12% Bis-Tris protein gels (1.5 
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mm, 15-well) with 2 µL Amersham™ ECL™ plex Fluorescent Rainbow 
Marker protein ladder (GE Healthcare). Gels were run in 1X MES 
SDS running buffer (Thermo Fisher) at 125 V for approximately 2 
hr before imaging with a Typhoon FLA 9500 laser scanner using 
the Cy3/Cy5 settings.
 After fluorescence imaging, gels were fixed in 50% MeOH and 
7% acetic acid in MilliQ water for at least 30 min and then 
stained with GelCodeTM Blue stain reagent (Thermo Fisher) 
overnight. After destaining in MilliQ water, the gel was imaged 
using a Gel DocTM EZ Imager (Bio-Rad).
Enrichment of ABP-labeled proteins for chemoproteomics analysis
Tissue lysate preparation is described in the Supporting 
Information. Tissue homogenate samples (500 µL) were normalized 
to 1 mg/mL protein concentration using 250 mM sucrose in PBS. 
Samples were incubated with PO or CPO competitor (1 µL of a 25 
mM stock in DMSO) or DMSO vehicle for 30 min at 37 C with 
agitation. Activity-based probes (1 µL of a 5 mM stock for 10 µM 
final concentration) or DMSO control was added to samples and 
incubated for 1 hr at 37 C with agitation. The final 
concentration of DMSO in all samples was 0.4% v/v. Click 
chemistry was performed using the following reagents for 500 µL 
of probe-labeled sample: 3 µL biotin-azide (10 mM in DMSO), 5 µL 
sodium ascorbate (500 mM in water), 5 µL tris(3-
Page 10 of 43
ACS Paragon Plus Environment






























































hydroxypropyltriazolylmethyl)amine (THPTA, 200 mM in water), and 
5 µL of CuSO4 (400 mM in water). The samples were then agitated 
at 37C for 1.5 hr. Precipitation of proteins was accomplished 
through the addition of 800 µL cold MeOH to each sample. Samples 
were then placed in a -80C freezer for 1 hr. Samples were 
centrifuged, supernatant discarded, and pellets air dried for 30 
min. To the samples, 520 µL of 1.2% SDS in 1X PBS was added. 
Samples were heated to 95C for 2 min and then sonicated for 6 s, 
1 s pulses. Samples were centrifuged and transferred to fresh 
Eppendorf tubes, leaving any residual pellet behind. A BCA assay 
was used to quantify the concentration of each sample. All 
samples were normalized to 0.65 mg/mL. 
All washes were performed using vacuum filtration. BioSpin 
disposable chromatography columns (Bio-Rad Laboratories) were 
prepared by rinsing twice with 1 mL 1X PBS. 100 µL streptavidin-
agarose beads were added to each column. The beads were rinsed 
twice with 1 mL 0.5% SDS in PBS and twice with 1 mL 6 M urea 
(prepared fresh in 25 mM NH4HCO3, pH 8), and four times in 1 mL 
1X PBS. Beads were transferred to 4 mL cryovials using 2 x 1 mL 
1X PBS. 500 µL of normalized probe-labeled lysate was added to 
corresponding Eppendorf tubes and another 500 µL of 1X PBS was 
added. The cryovials were then rotated for 4 hr at 37 C. Samples 
were returned to columns with two rinses of 1 mL PBS. Samples 
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were then washed twice with 1 mL 0.5% SDS in 1X PBS, 2 x 1 mL 6 
M urea (prepared fresh in 25 mM NH4HCO3, pH 8), 2 x 1 mL of 
MilliQ water, 8 x 1 mL 1X PBS, and 4 x 1 mL of 25 mM NH4HCO3 (pH 
8). Samples were then transferred to DNA lo-bind tubes 
(Sorensen) using 2 aliquots of 500 µL of 1X PBS. The tubes were 
centrifuged at 10,500 x g for 5 min at room temperature. The 
supernatant was discarded, and beads were re-suspended in 200 µL 
25 mM NH4HCO3 (pH 8). 0.08 µg trypsin (supplier) was added to 
each bead mixture followed by incubation overnight at 37 C with 
agitation.  Samples were then centrifuged at 10,500 x g for 5 
min and the supernatant was transferred to individually wrapped 
Eppendorf tubes. The samples were placed on a SpeedVac 
Concentrator (Savant SC110) until dry. Samples were 
reconstituted in 40 µL of 25 mM NH4HCO3 and heated at 37C for 5 
min with agitation. 40 µL of sample was transferred to 
thickwalled polycarbonate ultracentrifuge tubes (Beckman 
Coulter) and spun at 53,000 x g for 20 min. 25 µL of sample were 
then transferred to glass vials and stored at -20C.
Mass spectrometry and data analysis
Liquid chromatography with tandem mass spectrometry (LC-MS/MS) 
acquisition
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Probe-labeled and no-probe (NP) control samples were 
analyzed using a Velos Orbitrap (Thermo Fisher) instrument using 
High Resolution MS (HMS) – Low resolution MS (MSn) acquisition 
according to the method previously described by Sadler and 
coworkers.30 Briefly, samples were analyzed using a 100 min LC-
MS/MS method in which data were acquired 65 min after sample 
injection and 15 min into the LC gradient. Spectra were 
collected between m/z 400 to 2,000 at 100,000 resolution, 
followed by data-dependent ion trap generation of tandem MS 
(MS/MS) spectra of the six most abundant ions using 35% 
collision energy and a dynamic exclusion time of 30 s.
Probe-enriched data processing and analysis
Probe-enriched and NP-enriched brain and liver tissue 
sample data was analyzed independently using MaxQuant software 
(version 1.6.2.10)31 for feature detection and subsequent 
protein/peptide quantification. Datasets were grouped by 
treatment and MS/MS spectra was searched using a standard LC-MS 
run type against Mus musculus (strain C57BL/6J) UniProtKB 
database proteome file (UP000000589) (Downloaded in 04/12/2017 
containing 16,857 reviewed entries; 8 entries listed as obsolete 
as of 07/05/2017). N-terminal protein acetylation and methionine 
oxidation were selected as variable modifications for all 
datasets. Peptides and proteins were processed using a maximum 
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false discovery rate (FDR) of 0.01 (~ 1%). For increased 
peptide/protein (unique + razor) identification using small 
tissue sample collections, match between runs (MBR) was applied 
within an alignment time window of 20 min (3 min match window). 
Unique peptides (peptide fragment is unique to a single protein 
sequence in the proteome file) were used for continued analysis, 
requiring a minimum peptide length of 7 amino acids for matching 
to a protein. Additional MaxQuant parameters were ran at 
software default entries. 
Label-free quantification (LFQ) intensity data was log2 
transformed using the “proteinGroups.txt” output file, which 
required all unique peptide fragments to match to a single 
protein sequence in the .fasta file (protein count = 1; RAW Log2 
Pros tab), as described by Tyanova et al.31 LFQ values for each 
ABP control labeling group (PODA-ABP, CODA-ABP, and FOP-ABP with 
no PO or CPO inhibition) required an intensity values for  50% 
of the biological replicates for each not passing were excluded 
from further analysis. Protein values for ABP labeling were 
required to have a fold change (FC)  2 over NP controls before 
being statistically compared to inhibitions datasets (ALL Probes 
tab in Supporting Information). For competition experiments, 
protein targets were determined as inhibited by the authentic OP 
if a  2 FC decrease was observed when comparing treated to 
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untreated ABP measurements for each ABP.  Those ABP targets 
passing criteria in NP and competition experiments were placed 
in the BioCyc gene set enrichment tool for mapping proteins to 
known biological pathways (GO biological/molecular/cellular 
terms).32 Gene set enrichment was set at a p-value cutoff of less 
than 0.001 (~1% FDR) using a Fisher Exact statistical approach 
for determining the most significantly represented proteins 
belonging to metabolic pathways for the organism Mus musculus. 
Enrichment results represent the top 10 best scoring metabolic 
pathways and the most highly represented proteins for those 
pathways for each ABP treatment and tissue type.
Oxime reactivation of AChE
Electric eel AChE was diluted to 100 µg/mL and divided into 
130 µL volume samples. AChE was treated with a stoichiometric 
amount of OPs (3 µM) for 30 min at 22 °C, followed by 500 µM 2-
PAM for 1 hr. To remove any unreacted OP and excess oxime, 
samples were passed through a ZebaTM 7K MWCO spin desalting 
column (Thermo Fisher) which had been equilibrated with 3 x 300 
µL 1X PBS, according to the manufacturer’s instructions. The 
filtrate was collected and divided into 40 µL samples, which 
were then treated with 10 µM PODA, CODA, or FOP for 60 min at 22 
°C. Click chemistry using the previously described conditions 
was then performed. Cold methanol (80 µL) was added to each 
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sample to precipitate protein overnight at -70 °C. Precipitated 
proteins were isolated by centrifugation at 14,000 x g for 15 
min at 4 °C. The supernatant was removed by pipet and protein 
pellets were dried at r.t. Samples were reconstituted with 26 µL 
1.2% SDS in 1X PBS, 10 µL 4X LDS buffer, and 4 µL 10X reducing 
agent. Samples were denatured at 85 °C for 10 min and SDS-PAGE 
performed as described above. Densitometry was carried out using 
ImageQuantTL v8.1 analysis software; analysis of band 
intensities was performed using a rolling ball (radius 200) 
automatic background subtraction method for individual lanes. 
Band intensities were calculated and normalized to the average 
value of the vehicle control arbitrarily set to 1.
Results
Characterization of the OP ABPs using the Ellman assay 
showed that all three new ABPs were AChE inhibitors in the high 
nanomolar to micromolar range. The probes were 30-fold weaker 
inhibitors of AChE compared to PO and CPO (Figure 3). FP2, a 
previously described fluorophosphonate probe for serine 
hydrolases,33 performed comparably to PO and CPO as an AChE 
inhibitor, with a nanomolar IC50 value falling between the values 
determined for these two authentic OP pesticides.
Probe labeling of mouse tissue lysates and visualization by 
fluorescent detection on gels following SDS-PAGE showed distinct 
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protein labeling profiles in different tissue types (Figure 4). 
FP2 had the lowest intensity of labeling by fluorescence in all 
four tissue types, while CODA produced the most intense labeling 
of proteins. Bands which did not appear diminished by either PO 
or CPO competition were observed in all tissues, particularly 
for CODA, highlighting the importance of competitive ABPP when 
confirming protein targets.34
After qualitatively confirming successful labeling of 
protein targets and competition with OPs in various tissue types 
by fluorescence SDS-PAGE, we used an enrichment protocol and 
mass spectrometry analysis to identify protein targets in brain 
and liver. Two of the most abundant protein targets of OPs 
identified in mouse brain and liver by mass spectrometry, APEH 
and CES1, were confirmed by Western blotting (Figure S1). 
Chemoproteomics analysis using LC-MS/MS is a quantitative and 
highly sensitive technique compared to SDS-PAGE and can 
elucidate both diversity and relative abundances of targets 
across all samples. Average sequence coverage for the top 
protein targets in both tissue types was 27%. As shown in Figure 
5, ABP targets passing criteria against control and competition 
experiments resulted in 154 in brain and 179 in liver. 
Consistent with previous ABPP studies of OP targets, the probes 
clearly identified major serine hydrolase targets of OPs in both 
the liver and brain.16, 19, 35 Cholinergic targets AChE and BChE 
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were labeled by all three probes in the brain and labeling was 
completely abolished in the presence of PO and CPO. In liver, 
however, CPO competition decreased but did not eliminate 
labeling of BChE. CODA also labeled BChE to a lesser extent 
relative to the other two probes. All three probes labeled a 
variety of carboxylesterases in the liver and were sensitive to 
PO and CPO inhibition of these targets. Furthermore, various 
lipid metabolizing enzymes involved in the endocannabinoid 
signaling pathway, including MAGL, FAAH, and ABHD6, were 
identified primarily in brain tissue but also in liver, although 
coverage by the ABPs varied among these targets.
Notably, the fluorophosphonate probe FOP detected ~100 more 
targets in both brain and liver compared to the dialkyne probes 
PODA and CODA (Figure 4). In liver, FOP identified several 
glutathione S-transferases and cytochrome P450 enzymes, which 
were not detected using the other two probes.
Treatment of purified AChE that had been inhibited with PO 
and CPO was successfully reactivated by treatment with 2-PAM and 
could be visualized using the fluorescent detection on SDS-PAGE 
gels with the OP ABPs (Figure 6). Reactivation of AChE upon 
treatment with 2-PAM and recovery of enzyme activity was also 
confirmed through the Ellman assay (Figure S4).
Discussion
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Prior ABPP studies focused on identification of OP 
secondary targets have relied on fluorophosphonate-based probes, 
although OPs feature a range of different reactive groups, 
including phosphate esters with phenolic or thiol leaving 
groups. To explore the influence of probe structure on 
identified proteins, we developed a series of new OP ABPs 
featuring two different reactive groups, the fluorophosphonate 
and a previously unexplored dialkynyl phosphate ester, that 
would closely mimic the reactive and structural properties of 
authentic OPs such as PO and CPO. Validation of the OP ABPs 
using purified enzyme and tissue lysates established these 
probes covalently bind to their expected cholinergic targets and 
act as AChE inhibitors. The higher IC50 of the dialkynyl probes 
compared to the authentic OP pesticides may be attributed to the 
increased steric bulk of the propargyl compared to the ethyl 
groups.36 Further modification of the dialkynyl phosphate ester 
group, such as exploring asymmetric phosphate esters, may yield 
ABPs with improved reactivity as OP surrogates. Successful 
identification by CODA, PODA, and FOP of AChE in brain and BChE 
in brain and liver provided validation that all 3 probes 
covalently label these primary targets in tissue lysates; 
additionally, probe labeling was abolished by pretreatment of 
samples with CPO or PO, confirming that the PO and CPO compete 
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with the probes for interaction and binding to the protein 
targets.
Variation in identified targets and target distribution
The distribution of shared protein targets in brain 
compared to liver tissue varied depending on the probe type. In 
liver, PODA and CODA shared more targets with FOP than with one 
another (Figure 5). This suggests that structurally, the 
difference in leaving group has a larger influence on target 
labeling than the fluorophosphonate vs. the dialkyne warhead. 
However, in brain, PODA and CODA displayed more shared targets 
between each other than with FOP. Compared to 
fluorophosphonates, the dialkynyl phosphate ester warhead is 
less susceptible to hydrolysis and less reactive in vitro, 
yielding more selective protein profiles with more shared than 
unique targets. The higher reactivity of fluorophosphonate ABPs 
relative to dialkynyl phosphate ester probes may be attributed 
to a combination of sterics as well as leaving group ability, 
with the fluoride acting as a better leaving group than the 
phenolates in aqueous conditions.37
OPs have been extensively studied for their ability to 
inhibit serine hydrolases in a multitude of model systems. The 
role of these enzymes in neuropeptide turnover and regulation of 
signaling molecules in the nervous system may be of particular 
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interest for probing the cognitive impacts of OPs.38 Top serine 
peptidase targets in brain (Figure 5), including acylpeptide 
hydrolase (APEH),9, 39 prolyl endopeptidase (PREP),9, 15 cathepsin A 
(CTSA),40 and prolylcarboxypeptidase (PRCP)41 were perturbed by PO 
and CPO in relatively similar ways. In contrast, other 
peptidases identified in brain were primarily labeled by FOP, 
including isoaspartyl peptidase (ASRGL1), which may affect 
neurotransmitter production, and serine protease HTRA1,42 which 
may be involved in TGF-β signaling and β-amyloid precursor 
protein processing pathways.43
Impacts of organophosphates on lipid metabolism
Previous studies have used ABPP to examine pathways in 
mammalian model systems affected by OP exposures, frequently 
identifying significant numbers of enzymes involved in lipid 
metabolism for both brain and liver tissue.35 Paraoxon is known 
to inactivate a broad range of lipases in different tissues and 
has been used as a general lipase inhibitor in biochemical 
studies.44, 45 We confirmed our new ABPs performed as excellent 
mimics of authentic OPs through successful identification of 
major secondary targets of OPs by mass spectrometry-
chemoproteomics and validation of these targets through 
competition experiments. PODA, CODA, and FOP identified key 
enzymes involved in lipid metabolism, including several targets 
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in the endocannabinoid signaling pathway (FAAH, MAGL, and 
ABHD6),28, 46-48 acyl-protein thioesterases (LYPLA1 and LYPLA2), 
and platelet activating factor acetylhydrolases (PAFAH, 
PAFAH1B2, PAFAH1B). OP exposure levels that inhibit these 
targets in the brain may be well below the threshold for acute 
inhibition of AChE, underscoring the need for further 
investigation of the downstream effects of OPs on these 
sensitive signaling pathways. The probes did not label all of 
these targets in the same manner (Figure 5), indicating 
selectivity for some proteins depending on probe structure and 
reactivity. Given the importance of lipases and lipid signaling 
in brain,49-51 the effects of OPs on lipid metabolism has been 
proposed as a major contributing factor to the long-term 
negative impacts of OP exposure on development and cognitive 
function.52
Our OP ABPs represent new tools for profiling these 
important enzymes in the brain and other tissues that react with 
different OP structures. Furthermore, based on the results of 
this study, specific probes may be better suited for selective 
ABPP of specific lipases, or a cocktail of probes can be used 
for more comprehensive coverage of diverse lipid metabolizing 
enzymes. The varying sensitivities of lipid metabolizing enzymes 
to both OP competition and the different probes suggest the new 
OP ABPs developed in this study may be used to further probe 
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specific lipase targets by ABPP (Figure 5). These findings 
highlight the complexities involved with determining OP 
interactions with proteins using ABPP, and taken together, 
emphasize how differences in molecular structure and reactivity 
of both the authentic OPs and probes are crucial considerations 
in ABPP-based target identification.
Organophosphate hydrolases
Paraoxonases are organophosphate hydrolases (OPHs) that 
degrade OPs by catalyzing the hydrolysis of the leaving group, 
rendering the compound less electrophilic and generally less 
toxic. Paraoxonase-1 (PON1) is known to catalyze the hydrolysis 
of PO, CPO, and fluorophosphonate OPs such as sarin, soman, and 
VX,53 and has been proposed as a major factor influencing OP 
susceptibility on an individual basis.4, 53 Surprisingly, all 
three newly developed ABPs covalently labeled PON1 (Figure 5), 
which has not been previously reported in ABPP studies. The 
action of OPHs would mechanistically have been expected to yield 
hydrolyzed, and therefore inactive, probes. PODA was only 
partially competed by PO and CPO, while both CODA and FOP were 
highly sensitive to OP competition as enrichment was completely 
ablated by PO and CPO. These initial findings suggest PODA, 
CODA, and FOP may be useful ABPs for investigating PON1 activity 
in complex protein mixtures. Structural examination of the 
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hydrolytic abilities of PON1 have previously observed that 
steric modification of the alkoxy groups on the phosphate ester 
can lead to inhibition of the enzyme, with groups larger than an 
ethyl resulting in loss of OPH activity.54 Further exploration of 
the probe labeling site on PON1 is needed to determine the 
impact of OP ABP binding on OPH activity.
Points of convergence in OP targets
Since the increase in OP pesticide and nerve agent 
development in the mid-1900s, there have been intensive efforts 
to identify chemical medical countermeasures to mitigate the 
short-term effects of OPs, primarily through reactivation of OP-
inhibited AChE. However, the long-term effects of OP exposure 
remain poorly understood, but are thought to involve non-
cholinergic, secondary targets of OP compounds. Efforts to 
develop treatments for OP exposures are therefore focusing on 
therapeutics that will act on these secondary targets in 
addition to AChE.
Utilization of OP competition with the ABPP platform has 
allowed for streamlined, one-pot screening of multiple secondary 
targets of OPs in a given sample. Notably, identification of 
highly sensitive, shared targets across multiple tissue types 
and OPs may yield major points of convergence that can be 
pursued for broad spectrum therapeutic development. Following 
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identification of targets by ABPP, further validation using 
specific activity assays is needed to determine whether the 
enzyme targets are activated, inhibited, or unaffected by the 
labeling event. In our study, we identified MAGL, CTSA, APEH, 
PREP, and PRCP in both the brain and liver as major targets of 
all 3 probes with a broad range of affected pathways, including 
serine hydrolase and peptidase activities (Figure SI5). Having 
demonstrated these new probes can provide a measure of 
functional activity and OP sensitivity of these critical targets 
in complex protein mixtures, we envision application of this 
ABPP platform to more directed screening efforts of these and 
other targets for broad spectrum therapeutic and prophylaxis 
development in the future.
Oxime reactivators
The currently accepted treatment for nerve agent exposure 
in the U.S. involves intramuscular administration of atropine, a 
muscarinic agonist, and 2-pralidoxime (2-PAM), an N-oxime 
reactivator of AChE.55 However, the effectiveness of currently 
available therapeutic oximes, including 2-PAM, in reactivating 
OP-inhibited AChE in patients is controversial.56 Efforts that 
have centered on identifying oxime and non-oxime AChE 
reactivators must demonstrate compounds successfully reach key 
tissues, including the brain, remain stable under field storage 
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conditions, and display minimal toxicity and off-target effects. 
Most oximes developed for AChE reactivation also act as 
reversible AChE inhibitors and exhibit differential efficacy 
against various OP nerve agents and pesticides.5, 57, 58 
Furthermore, positively charged, bulky pyridinium N-oximes 
typically cannot cross the blood-brain barrier, although 
structural modifications to increase lipophilicity have 
facilitated penetration into the brain.59 Uncharged N-oximes as 
well as non-oxime AChE reactivators have been developed as 
possible alternatives.56, 60, 61 Other strategies to reduce toxic 
exposure to OPs have been explored, including prophylactics to 
prevent inhibition of AChE by OP agents62, 63 and screening or 
directed evolution of bioscavenger enzymes for stoichiometric or 
catalytic hydrolysis of OP compounds.64-68
Despite these diverse approaches to reversing or preventing 
OP toxicity, development of widely applicable compounds and 
strategies for therapeutic intervention following or preceding 
OP exposure continues to be a significant need. Delivery of 
therapeutics, their metabolism in vivo, and their dosage vs. 
concentration in target tissues are critical considerations. 
While reactivation or protection of the primary target, AChE, is 
essential for saving life, the potential long-term impacts of OP 
exposure due to effects on secondary targets are also an area of 
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concern that must be addressed in broad spectrum therapeutic 
development. 
We demonstrate that ABPP can be used as a platform to 
screen for therapeutics that reactivate AChE and potentially 
other enzyme targets. Treatment of PO- and CPO-inhibited AChE 
with 2-PAM successfully recovered the majority of enzyme 
activity as demonstrated by both the Ellman assay (Figure S3) 
and ABPP using these three new probes (Figure 6). We envision 
that this ABPP approach to screening candidate molecules will 
assist in the evaluation of drug compounds for reactivation of 
OP-inhibited cholinergic targets as well as enzymes involved in 
other diverse pathways. The flexibility of the ABPP platform and 
ease of probe application to samples will facilitate their use 
in therapeutic screening and target identification and may 
assist in discovery efforts for efficacious treatment and 
mitigation of both short- and long-term effects of OPs.
Conclusion
We have developed OP ABPs featuring different reactive 
groups, a fluorophosphonate warhead for serine hydrolase 
reactivity or a new dialkynyl phosphate ester reactive group to 
mimic the alkyl phosphate esters of OP pesticides. Applied to an 
ABPP platform, these probes yielded divergent protein profiles 
in mouse brain and liver tissues, demonstrating that probe 
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structure plays an important role in target identification and 
advocates for a probe cocktail approach to broadly identify and 
assess as many potential OP targets as possible. Competition 
experiments using PO and CPO also revealed variations in target 
distribution and sensitivity toward the different ABPs and 
selected OP pesticides; the fluorophosphonate probe FOP 
consistently labeled more unique targets, while the dialkyne 
probes PODA and CODA generated profiles with predominantly 
shared targets. These results provide a foundation for further 
refinement of the probe structures and inspiration for new probe 
designs, not only for ABPP of OP targets, but also for the 
development and evaluation of prophylactic or therapeutic 
treatments for OP exposure.
Our ABPP developments will enable deeper investigations to 
improve our understanding of OP impacts on human health. They 
represent a capability expansion that can be used in preventing 
and addressing the toxic effects of OP exposure. The search for 
broad spectrum therapeutics to treat the toxic effects of OPs is 
ongoing, and identification of shared targets for multiple OPs 
may provide focal points for advancing countermeasure 
development. Implementation of a streamlined ABPP platform using 
these probes for screening therapeutic candidate molecules 
across various animal models will enable evaluation of treatment 
efficacy for multiple targets in complex protein mixtures. 
Page 28 of 43
ACS Paragon Plus Environment






























































Moreover, ABPP can be used to investigate compounded or 
synergistic interactions in exposures involving multiple OPs or 
OPs with other toxicants, given the potential for individual OPs 
to interact with specific enzymes affecting downstream metabolic 
processes and signaling pathways. OP ABPs may also be leveraged 
to examine enzyme aging processes and spontaneous reactivation 
of protein targets, providing a comprehensive analysis of 
critical enzyme activities in complex samples using a suite of 
probes in one platform. Future application of the probes 
developed in this study to various animal models, tissue types, 
and in conjunction with various prophylactic or therapeutic 
strategies, will help support efforts to understand and address 
OP toxicity and potentially mitigate their impacts on 
susceptible populations.
FIGURES
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Figure 1. Pathways for reactivity and metabolism of OP 
pesticides. Oxidation of the thion to the more reactive oxon can 
lead to toxicity through enzyme inhibition and inactivation.
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Figure 2. Activity-based protein profiling (ABPP) using OP 
activity-based probes (ABPs). (A) Mechanism of covalent labeling 
of serine hydrolases by organophosphates and structures of 
selected OPs and OP ABP designs. The leaving group (blue) is 
essential for reactivity with nucleophilic residues in protein 
targets. Incorporation of the alkyne (green) into the OP ABPs 
allows for click chemistry to attach a fluorophore for SDS-PAGE 
or biotin group for pulldown of the protein-probe adduct and 
subsequent LC-MS/MS proteomics analysis. (B) ABPP workflow for 
standard target identification and validation using competitive 
ABPP.
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29.7 ± 7.1 nM 6.62 ± 1.74 nM
192 ± 69 nM1.09 ± 0.21 µM







Figure 3. Half maximal inhibitory concentration (IC50) 
determination for OP ABPs and authentic OP pesticides, 
establishing the relative effectiveness of these compounds as 
AChE inhibitors. Activity of electric eel AChE was determined 
using an Ellman’s assay after treating samples with OPs, ABPs, 
or DMSO vehicle (0.2% v/v) for 30 min. Symbols indicate data 
from three independent experiments. Error bars represent ± s.d. 
for each replicate.
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Figure 4. Protein targets identified by ABPP in mouse tissues 
using a suite of OP ABPs (PODA, CODA, FOP, and FP2), as 
visualized by fluorescent detection on SDS-PAGE gels. Mouse 
brain, kidney, lung, and liver tissue lysates were treated with 
DMSO vehicle, PO, or CPO (50 µM) for 30 min, followed by probe 
labeling (10 µM) for 1 hr at 37 °C and click chemistry with 
TAMRA azide for 1 hr. Stained protein images for these gels are 
in the Supplementary Information. NP = no-probe control.
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Figure 5. LC-MS/MS chemoproteomics identification of target 
distribution in mouse brain and liver S9 fractions. Venn 
diagrams show unique and shared OP-responsive targets for each 
probe. Heatmaps show sensitivities of targets to each probe and 
PO or CPO competition in brain and liver as averaged label-free 
quantification (LFQ) intensities. Proteins highlighted in red 
were identified as the most significantly represented targets of 
OP ABPs in a broad range of affected metabolic pathways in both 
brain and liver. Samples (n = 4) were treated with PO or CPO (50 
µM) or DMSO vehicle (0.4% v/v) for 30 min followed by labeling 
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with 10 µM probe for 1 hr at 37 °C. ABP target abundances were 
required to have a fold change  2 over no-probe control samples; 
additionally, results were filtered to exclude targets that were 
unresponsive to OP competition, determined using a fold change  
2. White boxes indicate targets for which there were missing 
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Figure 6. Oxime reactivation of OP-inhibited enzymes. (A) 
Mechanism by which OP-inhibited enzymes can be reactivated by 2-
pralidoxime (2-PAM). (B) Reactivation of 3 µM PO- and CPO-
inhibited eel AChE by 500 µM 2-PAM, determined by fluorescent 
Page 35 of 43
ACS Paragon Plus Environment






























































detection of OP ABP-labeled protein on SDS-PAGE gels. Error bars 
represent ± s.e.m. for 3 technical replicates. Full fluorescence 
and stained protein images of gels are in the SI.
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